Biotechnology company's shares dive 67% after drug failureBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7268.1039 (Published 28 October 2000) Cite this as: BMJ 2000;321:1039
- Roger Dobson
The United Kingdom's emerging biotechnology industry has suffered another bruising, with the share price of Cantab Pharmaceuticals plunging 67% after trials found that its treatment for recurring genital warts was no better than placebo.
A month earlier, shares in Scotia Holdings fell by 60% after it failed to get US regulatory approval for its leading drug for cancer. Last year in the wake of the first results from a programme of 10 randomised controlled trials of Marimastat, British Biotech's share price fell to an all time low.
According to the industry, these huge falls …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial